A carregar...
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the United States annually. Recurrent CDI (rCDI) affects ~25% of patients after completion of standard of care therapy and is associated with substantial health care costs and a ne...
Na minha lista:
| Publicado no: | Infect Drug Resist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301304/ https://ncbi.nlm.nih.gov/pubmed/30588042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S159957 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|